Gilead's (GILD) Yescarta Shows Positive Results as a First-Line Treatment for Patients With High-Risk Large B-cell Lymphoma
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/26/2026
- Equities end higher as Anthropic's IPO filing buoys AI stocks
- Anthropic files for Nasdaq IPO as revenue jumps to $16.3 billion
- Meta reverses losses to rise as investors weigh $35 billion AI funding plan
- Post-election relief ahead for markets, says Morgan Stanley
- Musk says SpaceX raised $40 billion in debt, warns of neocloud collapse
| Gilead Sciences (NASDAQ: GILD) | Delayed: 158.69 +2.65 (1.70%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $156.04 | 52 Week High | $108.63 | |||
| Open | $157.62 | 52 Week Low | $71.39 | |||
| Day High | $159.69 | P/E | 87.67 | |||
| Day Low | $157.52 | EPS | $1.81 | |||
| Volume | 6,237,016 | |||||
